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Abstract
Background: Aneurysmal subarachnoid hemorrhage (SAH) may be complicated by delayed cerebral ischemia,
which is a major cause of unfavorable clinical outcome and death in SAH-patients. Delayed cerebral ischemia is
presumably related to the development of vasospasm triggered by the presence of blood in the basal cisterns. To
date, oral application of the calcium antagonist nimodipine is the only prophylactic treatment for vasospasm
recognized under international guidelines.
In retrospective trials lumbar drainage of cerebrospinal fluid has been shown to be a safe and feasible measure to
remove the blood from the basal cisterns and decrease the incidence of delayed cerebral ischemia and vasospasm
in the respective study populations. However, the efficacy of lumbar drainage has not been evaluated
prospectively in a randomized controlled trial yet.
Methods/Design: This is a protocol for a 2-arm randomized controlled trial to compare an intervention group
receiving early continuous lumbar CSF-drainage and standard neurointensive care to a control group receiving
standard neurointensive care only. Adults suffering from a first aneurysmal subarachnoid hemorrhage whose
aneurysm has been secured by means of coiling or clipping are eligible for trial participation. The effect of early
CSF drainage (starting < 72 h after securing the aneurysm) will be measured in the following ways: the primary
endpoint will be disability after 6 months, assessed by a blinded investigator during a personal visit or standardized
telephone interview using the modified Rankin Scale. Secondary endpoints include mortality after 6 months,
angiographic vasospasm, transcranial Doppler sonography (TCD) mean flow velocity in both middle cerebral
arteries and rate of shunt insertion at 6 months after hospital discharge.
Discussion: Here, we present the study design of a multicenter prospective randomized controlled trial to
investigate whether early application of a lumbar drainage improves clinical outcome after aneurysmal
subarachnoid hemorrhage.
Trial registration: www.clinicaltrials.gov Identifier: NCT01258257
Background
Non-traumatic subarachnoid hemorrhage (SAH) is a
major cause of stroke accounting for approximately
1-7% of cases. In 80% of SAH-cases the source of bleed-
ing is a ruptured cerebral aneurysm [1,2]. Important for
a patient’s prognosis is the severity of the initial bleeding
and complications associated with the presence of blood
in the subarachnoid space. Once the aneurysmal SAH
has occurred patients are predominantly threatened by
two distinct problems in the acute phase. First, they
may experience a further, often more severe, hemor-
rhage, and second, they may suffer delayed neurologic
deterioration (DND) caused by delayed cerebral ische-
mia (DCI). The consequences of DCI may either be
transient or may result in cerebral infarction with persis-
tent neurologic disability or death.
The first problem, aneurysmal re-bleeding, is solved
through rapid cerebrovascular imaging and subsequent
treatment of the ruptured aneurysm, thus preventing
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formed either via craniotomy and surgical clipping of the
aneurysm or using endovascular techniques by occluding
the aneurysm with small platinum coils.
The second problem, DCI, is more difficult to recognize
and to handle. Patients after aneurysmal SAH experience
DND with an incidence of 30 to 60% [3]. It may be caused
by hydrocephalus, cerebral edema, fevers, seizures, electro-
lyte abnormalities, and DCI. Strongly associated with DCI/
cerebral infarction is a constringency reaction of the ves-
sels supplying the brain with blood, called vasospasm [4].
The pathomechanism leading to vasospastic vessel con-
striction is not completely understood [5] and the quanti-
tative relevance of vasospasm for the development of DCI
is less clear than previously assumed [6].
Clinical signs of DND accompanying radiographic
vasospasm are variable, depending on the affected blood
vessels including alteration of mental status, aphasia,
hemiparesis, or any other focal neurologic deficit. Often
the consequences of this condition may include perma-
nent neurologic deficits and death due to infarction and
subsequent herniation of the brain. DCI, DND and vasos-
pasm may be causatively interlinked, but also be indepen-
dently present from each other. Vasospasm may be
asymptomatic without clinically apparent deterioration of
the patient’s condition or external circumstances, such as
deep sedation, may prevent clinical detection of a dete-
rioration caused by vasospasm.
As DND is unspecific concerning its etiology, clinical
judgment, therefore, is unreliable for the prediction and
recognition of vasospasm. Thus digital subtraction angio-
graphy is the procedure of choice for the detection of
vasospasm. Vasospasm may be present in the proximal
vessels, the distal branches of the vasculature, or both.
Currently the only measure recognized for the preven-
tion of DCI is the prophylactic application of the calcium
channel blocker nimodipine [7]. Newer approaches, to
date not included in official guidelines but pursued in
several centers, include medication with statins and
magnesium [8].
One hypothesis claims that the likelihood of angio-
graphic vasospasm to occur is related to the amount of
blood in the basal cisterns. According to this considera-
tion, one prophylactic strategy is to remove as much of
this blood as early as possible. If clipping of the aneurysm
is performed this can be achieved intraoperatively by
opening the terminal lamina and irrigating the blood from
the basal cisterns. Albeit promising, studies addressing the
efficacy of this measure show inconclusive results [9]. This
approach is not feasible if the aneurysm is secured using
an endovascular approach.
Excess removal of cerebral spinal fluid (CSF) via an
external ventricular drain fails to prevent vasospasm and
may lead to a higher incidence of posthemorrhagic
shunt dependency [10,11]. Supposedly this is because
after aneurysmal SAH, the blood settles and clots in the
basal cisterns and therefore only CSF, being more light-
weight, is removed via the ventricular drain.
Application of a lumbar drain has been proposed as an
alternative approach to address clotting of the blood in the
basal cisterns. In two retrospective studies in patients after
aneurysmal SAH, the safetyo ft h i sa p p r o a c hw a ss h o w n
[12,13]. One of these studies addressed the radiologic and
clinical outcome after surgical clipping [12], while the
other addressed the outcome after endovascular coiling
[13]. Both studies led to a markedly diminished incidence
of angiographic vasospasm and improvement in clinical
outcome measured by the Glasgow Outcome Scale (GOS).
Therefore a prospective study addressing the efficacy of
this novel approach is warranted and currently being con-
ducted (EARLYDRAIN).
The aim of the EARLYDRAIN study is to examine the
efficacy of application of lumbar drainage in patients with
acute subarachnoid hemorrhage from a ruptured cerebral
aneurysm. The hypothesis is that early application of a
lumbar drain after aneurysmal SAH leads to an improved
outcome at six months after the hemorrhage, measured by
the modified Rankin score. Furthermore, it is hypothesized
that this postulated clinical effect will be due to a dimin-
ished incidence of cerebral vasospasm and delayed cere-
bral ischemia. Therefore the incidence of angiographic
vasospasm and the development of new infarctions shown
on CCT at discharge of the patient will be among the sec-
ondary endpoints of the present study.
Methods
Study design
The present study is in compliance with the Helsinki
Declaration. Ethical approval was obtained by the ethi-
cal committee of the medical faculty of the Friedrich-
Alexander-University Erlangen-Nürnberg (reference
number: 4171).
The EARLYDRAIN study is a 2-arm randomized con-
trolled trial to compare an intervention group receiving
early continuous lumbar CSF-drainage and standard neu-
rointensive care to a control group receiving standard
neurointensive care only. It is conducted by a German
national study group consisting of neurosurgical centers
treating at least 30 patients with aneurysmal subarach-
noid hemorrhage per year. Data management and moni-
toring will be performed by the Center for Stroke
Research Berlin (CSB) at Charité University Medicine,
Berlin, Germany.
Patients suffering from an aneurysmal SAH and com-
pleted elimination of the causative aneurysm are being
recruited for this study. The choice of the method of
aneurysm treatment is at the discretion of the neurovascu-
lar team taking care of a patient and not specified by the
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according to local guidelines and standard operating
procedures.
Subject Inclusion criteria
￿ Age: 18 years or older
￿ First aneurysmal SAH
￿ Pre-morbid modified Rankin Scale score 0 (“no
symptoms at all”)o r1( “no significant disability
despite symptoms”)
￿ Aneurysm treatment performed during the first 48
hours after the initial hemorrhage.
￿ Informed consent by the patient or his/her legal
representative. In case neither the patient is capable
of giving informed consent nor a legal representative
is available, informed consent can be given by an
independent physician neither involved in the
patient’s treatment nor in conducting the trial.
Subject Exclusion criteria
￿ Subarachnoid hemorrhage of other than aneurys-
mal origin
￿ No hemorrhage visible on initial CCT-scan (Fisher
Grade I)
￿ Pregnancy
￿ Concurrent participation in another interventional
trial (participation in an observational trial is not an
exclusion criteria)
￿ Life expectancy less than 1 year for other reasons
than the current SAH
￿ Other concomitant severe disease that would con-
found with treatment
￿ Other clear contraindication for treatment with a
lumbar drain (e.g. absent or compressed basal cis-
terns on the admission CCT)
Interventions
In order not to provoke premature rupture of the aneur-
ysm due to accidental drainage, randomization to the
study and eventual placement of a lumbar drain takes
place after securing the aneurysm by the preferred method
of choice (Figure 1). Every patient in the lumbar drainage
group (LD-group) receives a lumbar drain during anesthe-
s i ar e q u i r e df o rt h ea n e u r y s mt r e a t m e n t .I n s e r t i o no fa
lumbar drain into the subarachnoid space is conducted in
standard fully sterile technique. This is to be performed
before anticoagulation or anti-platelet therapy is initiated,
which sometimes is warranted after endovascular coiling.
A post-procedural CCT scan of the brain is performed
within 24 hours after aneurysm treatment. In case of neu-
rological worsening after the procedure it is strongly
recommended to perform the follow-up CCT-scan as
soon as possible.
In patients in the LD-group, CSF drainage via the lum-
bar drain is started slowly and steadily at a rate of approxi-
mately 5 ml per hour after the post-interventional CCT.
This leads to a planned daily CSF-drainage of 120 ml per
day through the lumbar route. Patients in both groups
may receive additional CSF drainage via a ventricular
device. The amount of CSF drained via the ventricular
route is determined according to clinical requirement and
not specified by the study protocol.
In order to enhance accuracy of the amount of CSF
drained, regular drainage control every other hour and
stopping in case of excess drainage is strongly recom-
mended by the principal investigators. In case of neurolo-
gical decline suspiciously related to the lumbar drainage,
the drain must be closed immediately. Drainage may be
gradually restarted after 12 to 24 hours, after performing a
CCT scan.
If the post-procedural CCT or any other follow-up CCT
scan shows compressed basal cisterns or any signs of
threatening herniation, lumbar CSF diversion in the LD-
group must not be performed. It may still be feasible to
carefully drain CSF via the lumbar route [14], but this is at
the discretion of the local investigator and not recom-
mended. In patients requiring sedation and mechanical
ventilation, either due to neurological impairment or for
other medical reasons, intracranial pressure monitoring is
mandatory. This may be performed according to local pol-
icy either with parenchymal or ventricular devices. If the
intracranial pressure exceeds 20 mmHg, further CSF drai-
nage via lumbar route shall be interrupted until the ICP is
below 20 mmHg again. Careful CSF-drainage via the lum-
bar route may still be feasible in case of high intracranial
pressure [14], but again this is at the discretion of the local
investigator. A method of detecting the safety of lumbar
CSF diversion may be determining the gradient of lumbar
versus intracranial CSF pressure [15]. Albeit promising,
the Earlydrain investigators explicitly rate this approach
preliminary and experimental. In case of doubt, lumbar
CSF diversion must not be performed.
Further neuromonitoring with transcranial duplex sono-
graphy (TCD), electroencephalography (EEG), brain tissue
oxygenation recordings, jugular bulb oxymetry, regional
cerebral blood flow measurement, microdialysis or other
methods is at the discretion of the center and according to
its local guidelines. As far as possible, this data should be
saved electronically for post-hoc analysis.
A CCT scan as well as conventional digital subtraction
angiography (DSA), CT angiography or MR angiography
for assessment of vasospasm in the larger vessels is rou-
tinely performed on day 7 to 10 after the initial hemor-
rhage, according to local guidelines. In case of the
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the cause, angiography may be performed at any time. If
it is performed earlier than day 7 to 10 and the patient
shows no clinical deterioration thereafter, the angiogra-
phy on day 7 to 10 is omitted. Treatment of radiogra-
phically confirmed vasospasm is according to local
guidelines and not specified in the Earlydrain study pro-
tocol. It may include augmentation of cerebral blood
flow via hypertensive hypervolemia as well as endovas-
cular balloon dilation or intraarterial infusion of
vasodilators.
After cerebrovascular imaging on day 7 to 10 the lum-
bar drainage of CSF is stopped in the LD-group. If cere-
brovascular imaging is carried out before day 7, lumbar
drainage is stopped on day 8. It may be pursued on a
clinical base, as required.
Amount and duration of CSF drainage
Patients randomized to the lumbar drainage group shall
receive a daily drainage of 120 ml CSF, or 5 ml per
hour for seven days. If higher amounts of CSF need to
be drained on clinical grounds as in patients with hydro-
cephalus, this is preferably performed via an external
ventricular drain.
The drain is planned to remain in place until the con-
trol angiography on day 7 to 10 after the initial hemor-
rhage. The local investigator may decide to remove the
drain earlier in patients fully mobilized without clinical
necessity of CSF drainage. However, consecutive drainage
should not be less than four days to achieve a valid study
result. Lumbar CSF drainage may be prolonged beyond
the control angiography on clinical requirement. The
amount of CSF drainage may then be adjusted to clinical
requirements and bears no further restriction.
Patients randomized to the control group should not
receive a lumbar drain before the planned control angio-
graphy to be performed on day 7 to 10 after SAH. If the
patient develops hydrocephalus, and no EVD was placed
initially for CSF drainage, a lumbar drain may be installed
at the discretion of the local investigator. These patients
are analyzed in the intention-to-treat analysis, but are not
suitable for the per-protocol analysis.
Consent to study participation
Consent to study inclusion is sought after explanation
and agreement to a specific aneurysm treatment. Thus,
patients capable of consenting to the aneurysm treatment
will be informed about the study details themselves and
SAH Both groups
CSF-drainage via eVD as required
Aneurysm 
treatment
LD
NoLD
48 hours 24 hours
7-10 days
after SAH
LD group
CSF -drainage via LD (5 ml/h)
CT-scan +
optional: angiography 
or CTA or MRA
on day 7-10
insertion of lumbar drain
control group 
(no lumbar drain)
Patient‘s consent 
to aneurysm 
treatment and 
study inclusion Randomization
CT-scan on
post-treatment
day 1
Modified Rankin
scale score at 
6 months 
after discharge
EARLYDRAIN study algorithm
CT-scan 
before discharge
Figure 1 EARLYDRAIN study algorithm. The EARLYDRAIN study algorithm showing the course of events after the initial aneurysmal
subarachnoid hemorrhage (SAH) and the subsequent surgical or interventional aneurysm treatment. The study includes two groups, a treatment
group receiving lumbar CSF-drainage (LD) and a control group receiving no lumbar drainage according to protocol (NoLD). The timing of the
patient’s consent to study participation, randomization, cranial imaging and assessment of clinical outcome is indicated by the shaded boxes.
Imaging on day 7 to 10 is scheduled according to local guidelines. If a local center performs no routine cerebrovascular imaging for vasospasm
screening in patients without clinical suspicion, it may be omitted.
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able of consenting to the proposed treatment, the legal
representative should be informed on the conditions of
treatment choices and afterwards, on the details of the
EARLYDRAIN study. A patient may be randomized if
the legal representative gives informed consent to the
study, based on the presumed will of the patient. If
neither the patient is capable of giving informed consent
nor a legal representative is available in due time, an
independent physician not involved in the patient’s treat-
ment nor in the trial may be asked for study approval.
The latter option reflects a distinct characteristic of Ger-
man law and the local ethic committee may or may not
permit this.
This option was introduced into the consent procedure
because the aforementioned retrospective data on lumbar
drainage for treatment of aneurysmal SAH suggests a
potentially beneficial effect of the measure for the patient.
Therefore it shall not be categorically withheld from
patients who are not capable of deciding whether to par-
ticipate in the study or not and who do not have a legal
representative.
However, in these cases of deferred consent, a legal
representative needs to be established as soon as possible,
according to German law. From our experience this legal
procedure requires a time period from proposal to estab-
lishment of a legal representative of up to 72 hours, thus
requiring the consent of an independent physician upfront
for study inclusion. As soon as a legal representative is
available and/or the patient is capable again to consent to
the study, he or she must be asked to give informed con-
sent. If the patient or his/her legal representative refuses
consent after inclusion by advice of an independent physi-
cian, the patient’s further study participation is no longer
possible. In this case, however, the patient or his/her legal
representative is asked to give consent for evaluation of
already acquired data.
The detailed explanation of the study to the patient,
legal representative or independent physician has to be
carried out using appropriate explanations and words
depending on the previous medical knowledge of the
respective person and her/his level of education. During
the explanations the respective person will be asked on a
regular basis if she/he understands the conveyed infor-
mation and if any questions have arisen. In addition to
these verbal explanations the patient/legal representative/
independent physician will be given a leaflet containing
the study details. After reading the leaflet the respective
person will be given as much time as she/he demands for
the decision on study participation.
Randomization
Any patient meeting the inclusion criteria and not vio-
lating the exclusion criteria may participate in the
EARLYDRAIN study and be randomized to either
receive a lumbar drain or not, thus defining the two dis-
tinct groups LD and NoLD.
Randomization is performed via a dedicated internet site
accessible for all local investigators of the participating
trial centers http://www.randomizer.at. No stratification or
minimisation is to be used. The security measures of the
online randomization system “randomizer.at” include that
1. All transactions are logged, 2. The audit trail of the trial
can be accessed and analysed any time by the trial moni-
toring committee. 3. Network traffic between the web-
browser and the randomizer is encrypted using SSL
(Secure Sockets Layer) with strong encryption.
Sample size calculation
In the ISAT trial, the largest trial on the treatment of
aneurysmal subarachnoid hemorrhage so far, the mortality
at one year follow-up was 8.1% to 10.1% [16]. Given the
data from both retrospective studies on lumbar drains
after SAH, a reduction from 15% to 2.1% after coiling and
from 5% to 3% after clipping was shown. Thus, both stu-
dies were way lower in their mortality rate and, therefore,
their external validity may be questioned.
In the two retrospective trials, 167 [12] and 107 [13]
patients were studied, respectively. The effect of lumbar
drainage was a decrease of the incidence of “clinical vasos-
pasm” by 34% [12] and 40% [13], respectively.
In the above-mentioned studies the term “clinical vasos-
pasm” includes neurological deterioration not explainable
by hemorrhage, cerebral edema, hydrocephalus, hypona-
tremia, drug toxicity, infection or seizures. No distinction
is made between delayed cerebral ischemia (DCI) and
vasospasm as potential causes of the clinical worsening.
The following statistical calculations are based on the
assumption that the clearly defined subtype of “delayed
neurological deficit” measured in the above-mentioned
two retrospective trials is highly correlated with clinical
outcome 6 months after SAH, which constitutes the pri-
mary endpoint of the EARLYDRAIN study.
For lack of previous studies assessing clinical outcome
after lumbar drainage in SAH as a primary endpoint
this assumption seemed justified.
To assess a decrease of the incidence of DND from 40%
to 20% in a prospective clinical trial, 93 patients in each of
the two study arms are required to gain a power of 85%,
using an alpha error of 5%. To account for possible imbal-
ances in the randomization procedure concerning severity
of clinical and radiological grading of the SAH or the
choice of treatment and to facilitate a preplanned analysis
on the severity of the initial hemorrhage, the planned
study size is to include and randomize altogether 300
patients. This results in a power of 85.2%, again, using an
alpha error of 5%, to detect a decrease in the rate of severe
disability on a dichotomized modified Rankin scale from
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from the retrospective trials on a dichotomized GOS
[12,13]. The EARLYDRAIN investigators are aware of
other, more conservative calculations for the sample size
of patient-centered outcome studies targeting vasospasm,
indicating that there may be the necessity to include more
than 5000 patients in a single trial [17]. The power calcula-
tions, as described above and based on the available retro-
spective data, do not substantiate numbers this large.
Besides feasibility issues, clinical experience from the prin-
cipal investigators considering the expected effort-benefit
ratio does not warrant enlargement of the trial to detect a
rather small difference between groups.
Safety of lumbar drains after aneurysmal SAH
In the above-mentioned two retrospective studies, mortal-
ity was lower in the lumbar drainage group. Neither of the
retrospective studies mentions procedural related compli-
cations for the lumbar drains [12,13]. In patients with
increased intracranial pressure, careful lumbar drainage of
CSF may be a possible treatment even in case of com-
pressed basal cisterns [14]. A feasible strategy to enhance
safety is determination of the lumbar-cranial pressure gra-
dient and cessation of lumbar CSF diversion in patients
with increasing pressure difference [15].
However, in patients presenting increased intracranial
pressure or compressed basal cisterns on CCT-scan the
risk associated with lumbar drainage is unclear according
to the current state of medical knowledge. In unclear cases
the investigator must refrain from the insertion of a lum-
bar drain.
Outcome assessment
The primary endpoint is disability after 6 months, assessed
by the modified Rankin Scale [18] dichotomized at a score
of 0 to 2 versus 3 to 6 (6 = death). Assessment is per-
formed by a blinded investigator of the local study center
by personal visit. Alternatively, a telephone questionnaire
is suitable for outcome assessment using the modified
Rankin Scale [19]. Outcome assessment is planned to be
done on the whole dataset as well as in preplanned strati-
fied subsets (i.e. for example clinical SAH grade according
to the Hunt&Hess scale 1-2 vs. 3-5 [20], CT grading
according to Fisher I-III vs. IV [21]).
Secondary outcome criteria are:
￿ Mortality after 6 months
￿ mRS score after 6 months as continuous variable
￿ Angiographic vasospasm on day 7 to 10, as defined
by a caliber reduction by 33% or more compared to
the initial digital subtraction angiography
￿ Endovascular rescue therapy performed due to
proven vasospasm, using balloon dilation of spastic
vessels and/or arterial infusion of vasodilators
￿ Infarction (due to vasospasm) in the last CT scan
before discharge
￿ Expression of clinical delayed neurological deficit
after the aneurysmal SAH until discharge from acute
care.
￿ Daily course of TCD mean flow velocity in both
MCA at a depth of 50-60 mm
￿ Rate of death during the initial hospital treatment
after the aneurysmal SAH.
￿ Rate of CSF shunt insertion during the first six
months
￿ Presence of CSF infection during the first 14 days, as
defined by modified CDC criteria for device-associated
meningitis (treatment required on either positive cul-
ture, or elevated cell count, red cell/white cell ratio,
increased lactate and/or decreased glucose) [22].
The following parameters will be recorded and used in
predictor-/association models concerning primary and/
or secondary outcome parameters:
￿ Gender
￿ Age
￿ Hunt&Hess grade on admission
￿ Time from symptom onset to admission
￿ Location of aneurysm
￿ Time from symptom onset to aneurysm treatment
￿ Treatment of aneurysm by clipping or coiling or
both
￿ Time from symptom onset to randomization
￿ Time from symptom onset to treatment start (i.e.
insertion of the lumbar drainage in the treatment
arm)
￿ Time from admission to discharge
￿ Insertion of EVD (yes/no)
￿ Duration of EVD being in place
￿ Duration of lumbar drainage
￿ Amount of CSF drained by EVD [ml]
￿ Amount of CSF drained by lumbar drain [ml]
￿ Use of nimodipine (yes/no)
￿ Use of statins (yes/no)
￿ Use of Mg
2+ (yes/no)
￿ Transcranial Doppler ultrasound in both MCA at
50-60 mm depth, 1x daily (> 160 cm/s versus < 160
cm/s)
￿ Presence of CSF infection during hospital stay (yes/
no)
Data Management and Monitoring Body
All data specified in the trial protocol will be documented
in the patient’s records and on standardised Case Report
Forms (CRFs), available as original with two copies. The
investigating physician is responsible for appropriate
completion of the form. The (CEHRIS) of the Center for
Stroke Research Berlin (CSB) is responsible for data base
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rage, and validation. Data validation includes controls of
completeness, consistence and plausibility of the data
documented in the CRF using a query system between
data management and investigating physician. After reso-
lution of all queries concerning enrolled patients, the
data bank is closed (end of the trial) and forwarded to
the biometrician for the purpose of evaluation. After fina-
lization of all evaluations the final report and all original
CRFs are delivered to the principal investigator.
The trial is supervised and monitored by the Intensive
Care Treatment of Stroke group (ICTOS) of the CSB
including initiation and regular site visits, source data
verification, and reports of adverse events. All data man-
agement and supervising procedures are performed
according to Standard Operation Procedures (SOPs) of
the CSB and in accordance to ICH-GCP Guidelines (E6)
and the declaration of Helsinki.
Adverse events (AE) and severe adverse events (SAE)
Apart from AE and SAE which may occur after the
beginning of the trial (synchronous with the insertion of
the LD) there are complications related to securing the
aneurysm:
Surgery-related complications: Surgical treatment
includes the known risks of surgical interventions.
Complications related to endovascular therapy: Endo-
vascular therapy includes the risks known to be asso-
ciated with it.
Definition of adverse events and severe adverse events
The term “adverse event” (AE) describes any sign, symp-
tom, syndrome or any disease 1. occurring newly in a
trial participant after consent to the trial and 2. being of
particular interest for the assessment of the disease or
the security of the therapeutic concept. In this trial AEs
include:
￿ Arterial or venous thrombosis,
￿ Complications related to insertion of a lumbar
drainage,
￿ Any SAE
The term AE does not implicate a causal correlation
with the participation in the trial. Surgical or endovascu-
lar interventions are not necessarily considered as AE
but can be necessary for the therapy of an AE. AEs are
divided in severe (SAE) and non-severe (AE) adverse
events.
An SAE is any AE occurring during the trial that is
related to:
￿ Death
￿ Any life-threatening condition,
￿ Re-hospitalisation or prolongation of hospitalisation,
￿ Long-term or severe restraint of the state of health, or
￿ Birth deformities.
Documentation
Investigation of AEs is part of every assessment of the
study participants. Any AE has to be documented in the
CRF.
E v e r yS A Eh a st ob ed o c u m e n t e do nas p e c i a ld o c u -
mentation form and has to be reported within 24 hours
after recording, but at least at the next working day, to
the data monitoring center in Berlin.
Statistical Analysis
All data are described according to their mean, median or
frequency, as applicable. The dichotomized modified Ran-
kin score as primary outcome variable is investigated in
using univariate analysis. Multivariate logistic regression
modeling is performed accordingly, adjusted for clinical
grade, fisher grade, ventricular hemorrhage, parenchymal
hemorrhage, gender, nimodipine or other concomitant
medical treatment. Analysis is planned as intention-to-
treat as well as per protocol, excluding the patients who
were treated with amounts of CSF drainage via lumbar
drain deviating from the specified 5 ml/h or which needed
a lumbar drain when randomized to the No-LD group.
Interim Analysis
An interim analysis after inclusion of 10 patients will
address safety issues. This analysis focuses on the sec-
ondary endpoints and SAEs only, especially the rate of
death during hospital stay. During the interim analysis,
the recruitment for the EARLYDRAIN study is not
stopped. The frequency of further safety analyses will be
adjusted to the recommendations of the data and safety
monitoring board (DSMB).
Data and Safety Monitoring Board (DSMB)
Safety aspects of the trial are supervised by the DSMB.
The DSMB consists of an independent stroke physician, a
neurosurgeon, and a neurointensivist, neither involved in
the planning nor conduction of the trial nor participating
in the trial. The DSMB independently elects a chairman.
The DSMB is responsible for critical evaluation and sug-
gestions for improvement of the trial protocol and super-
vision of the trial course. The DSMB has to be informed
about the results of safety issues, especially the number of
AEs and SAEs in each treatment group at least after every
10 patients having been enrolled, but at least every 6
months starting with the day of inclusion of the first
patient, but also whenever the Steering Committee
believes this to be necessary. Based on the results of safety
aspects the DSMB will recommend to continue or stop
the trial. The members of the DMSB confer personally or
via telephone and report their recommendations to the
Steering Committee.
Steering Committee
The steering committee consists of the neurosurgical
(Stefan Wolf, principal investigator) and the neurological
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Page 7 of 9(Jürgen Bardutzky) project manager along with the
directors of the two leading trial centers (Stefan Schwab
and Peter Vajkoczy). The Steering Committee is respon-
sible for planning of the trial including funding, develop-
ment of the trial protocol in cooperation with the
participating centers, design of patient’s and legal repre-
sentative’s information and informed consent, approval
of the trial protocol and informed consent including
later amendments by legal authorities and ethics com-
mittees, selection, verification, and recruitment of poten-
tial trial centers, design of the CRF, organisation of a
randomization system on a 24-hours/7-days basis
including a trial-phone hotline. Based on the recom-
mendations of the Data Safety and Monitoring Board
(DSMB) the Steering Committee decides on preliminary
termination of the trial. The Steering Committee can
also stop the trial preliminarily, if advised so for other
reasons by the DSMB. Furthermore the Steering Com-
mittee has to give consent to reports and publication of
trial results.
Discussion
Here we describe the design of a multi-center prospec-
tive randomized controlled trial to investigate whether
early lumbar drainage improves clinical outcome after
aneurysmal subarachnoid hemorrhage.
If one assumes that the primary hemorrhage usually
occurring outside of the hospital is difficult to prevent
because carriers of aneurysms are usually asymptomatic,
then - apart from elimination of the aneurysm itself -
delayed cerebral ischemia due to radiographically detect-
able vasospasm constitutes the most important aspect of
aneurysmal SAH that causes substantial morbidity and
mortality. The pathophysiological mechanisms underlying
either of these entities and possibly influencing each other
have not been understood sufficiently. Arterial narrowing
as seen on angiography may be highly correlated with
unfavourable clinical outcome but it is assumed that out-
come-defining factors are more diverse [6]. To account for
the complexity of factors causing early clinical deteriora-
tion after aneurysmal SAH the rather abstract term
“delayed neurological deficit” has been created. However
not only the interaction between these factors but also
their influence on clinical long-term outcome remain
speculative.
T h ep r e s e n ts t u d yi sb a s e do nt h eb e l i e ft h a ti nt h e
majority of cases DND is caused by angiographically
detectable arterial narrowing and that the occurrence of
DND, including DCI, and radiographic vasospasm are
major factors for unfavorable outcome.
Since the development of nimodipine as a prophylactic
agent against DND and DCI no new treatment strategies
have been included in international guidelines. This
emphasizes the necessity of new ways to approach pro-
phylaxis and therapy of DCI.
The hypothesis that lumbar drainage may improve out-
come after SAH was derived from the results of two pre-
vious retrospective investigations that have suggested a
beneficial effect concerning the development of clinical
deterioration [12,13]. However, the aforementioned stu-
dies used development of “clinical vasospasm” as primary
endpoint whereas in the EARLYDRAIN study the pri-
mary endpoint is degree of disability after 6 months
assessed in a prospective blinded manner using the mRS-
score. Thus EARLYDRAIN focuses on clinical outcome,
allowing direct conclusions about the benefit of early
lumbar drainage in patients having experienced an aneur-
ysmal SAH. Furthermore by choosing clinical outcome as
the primary endpoint the authors of the present study
tried to avoid ambiguity due to heterogenous believes
concerning the etiology of DND and the role of radio-
graphic vasospasm as an outcome-influencing factor or a
mere epiphenomenon, respectively.
The focus on clinical outcome is also a feature that
clearly distinguishes the EARLYDRAIN study from the
LUMAS trial ("Lumbar drainage after subarachnoid
hemorrhage”, NCT00842049). This study has been com-
pleted in February 2011 and its results are awaited.
The LUMAS trial is a Phase II randomized clinical trial,
the primary endpoint is the incidence of delayed ischemic
neurologic deficits within three weeks after the initial
hemorrhage. Clinical outcome according to the modified
Rankin Scale score at 10 days and 6 months after the
ictus are among the secondary outcome measures. The
focus of LUMAS are efficacy of lumbar drainage after
aneurysmal SAH with respect to the primary endpoint.
The results of this trial will be studied carefully by the
EARLYDRAIN-investigators with regard to efficacy and
safety of the employed methods. Because of reverse, but
comparable primary and secondary endpoints of the two
studies their results offer the opportunity of a combined
analysis.
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